Bristol Myers Squibb
Transforming patients' lives through science
- B2B
- Has physical offices
- Publicly traded
- Manufacturing
- Healthtech
- Multi-product
- Sales-led purchase
About Bristol Myers Squibb
This company works to transform patients' lives through science by developing innovative therapies and promoting health equity for those affected by serious diseases
Key facts
- Industry
- Pharmaceutical Manufacturing
- Company size
- 10,000+ employees
- Headquarters
- Lawrence Township, New Jersey, United States
- Revenue
- $48.2BFY2025, publicly reported
- Website
- bms.com
Jobs at Bristol Myers Squibb
- Specialist, QA Operations Shopfloor
- Software Engineer II, Analytics Operations
- Vice President, Data, Analytics, AI & Technology
- Senior Director, Head of Commercialization Data and AI Delivery
- Manager, Pharmaceutical Product Development GenAI & Data Science
- QA lead technical operations
- Specialist, QA Manufacturing Shop Floor Operations
- Senior Manager, Data Protection & Insider Risk - Asia
Bristol Myers Squibb in the news
- Bristol-Myers Squibb vs. Johnson & Johnson: Comparing Quarterly Revenue Scale
Bristol Myers Squibb and Johnson & Johnson are both showing slow revenue growth, with J&J having a larger revenue base and a growing medical technology division, while Bristol Myers Squibb recently secured regulatory approvals and is expanding manufacturing.
- U.S. Food and Drug Administration Approves Expanded Indication for Bristol Myers Squibb’s CAMZYOS® (mavacamten) for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) in Adults and Pediatric Patients
The FDA approved Bristol Myers Squibb's CAMZYOS (mavacamten) for an expanded indication to treat symptomatic obstructive hypertrophic cardiomyopathy in adults and pediatric patients.
- Bristol Myers Squibb secures expanded US approval for Camzyos
The FDA expanded approval for Bristol Myers Squibb's Camzyos to treat symptomatic obstructive hypertrophic cardiomyopathy in pediatric patients aged 12 and older.
- Bristol Myers Squibb (BMY) Reported 41.1% MRD Negative Responses In Phase 3 Trial
Bristol Myers Squibb announced positive Phase 3 trial results for ZENBEXUS in multiple myeloma, showing a significant advantage in MRD-negative complete responses.
- Bristol Myers Squibb (BMY) Stock Trades Below Fair Value As Caution Lingers
Bristol-Myers Squibb's stock is trading below its intrinsic value despite significant gains and strong drug pipeline data, suggesting investor caution.
Bristol Myers Squibb at a glance
Bristol Myers Squibb is a B2B company in the Pharmaceutical Manufacturing industry, headquartered in Lawrence Township, New Jersey, United States.
Bristol Myers Squibb has 10,000+ employees.
Bristol Myers Squibb's revenue is $48.2B (FY2025, publicly reported).
Bristol Myers Squibb is hiring: 8 recent open roles, including Specialist, QA Operations Shopfloor, Software Engineer II, Analytics Operations, Vice President, Data, Analytics, AI & Technology.
Selling to companies like Bristol Myers Squibb?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companies